Drug class profile · refreshed daily from federal data

Dihydrofolate Reductase Inhibitor Antibacterial

2 molecules in this class, $15.8M combined CY2024 Part D spend across 277K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Dihydrofolate Reductase Inhibitor Antibacterial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $15.8Mcombined across class
Total Rx claims: 277K93K unique beneficiaries
Generic mfrs (active): 7across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Trimethoprim

277K Part D claims (CY24) · 93K beneficiaries · First FDA approval: 2011-06-24

3 generic mfrs 0 plans require PA

Low NADAC$1.23

→

Avg plan cost$1.23

Part D spend $15.8M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Polymyxin B and Trimethoprim

Brand: Polymyxin B Sulfate and Trimethoprim · — Part D claims (CY24) · First FDA approval: 1997-02-14

4 generic mfrs 0 plans require PA

Low NADAC$0.453

→

Avg plan cost$0.453

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.